Volume 5 Supplement 1

Proceedings of the 12-th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)

Open Access

Phase IIA trial of 1% topical cidofovir for treatment of high-grade perianal squamous intraepithelial neoplasia in HIV-infected men and women (AMC046)

  • Elizabeth A Stier1Email author,
  • Stephen E Goldstone2,
  • Mark H Einstein3,
  • Naomi Jay4,
  • J Michael Berry4,
  • Timothy Wilkin5,
  • Jeannette Lee6,
  • Lori Panther7,
  • David Aboulafia8 and
  • Joel Palefsky4
Infectious Agents and Cancer20105(Suppl 1):A60

https://doi.org/10.1186/1750-9378-5-S1-A60

Published: 11 October 2010

Objective

Treatments for high-grade perianal intraepithelial neoplasia (PAIN 2-3), include surgical ablation/excision and have significant morbidity and recurrence rates. Cidofovir, a cytidine nucleotide analogue, has broad-spectrum antiviral activity. This multicenter study prospectively evaluated the efficacy, safety, and tolerability of topical cidofovir for treatment of PAIN 2-3 in HIV-positive individuals.

Methods

HIV-positive patients with biopsy-proven PAIN 2-3 ≥ 3 cm2 were eligible. Subjects applied 1% topical cidofovir for 6 two-week cycles consisting of 5 consecutive days of treatment and 9 days without treatment. Subjects were evaluated every 2 weeks. High-resolution anoscopy and biopsy were performed 6 weeks after the last cycle. Results were scored as stable disease (SD), partial response (PR) (> 50% reduction in size), complete response (CR), or progressive disease (PD) based on size and histology.

Results

24 men and 9 women were enrolled. Mean age was 33 years, median HIV RNA level was <75 copies/ml, and mean CD4 count was 440/µl. HPV DNA was detected in intra-anal swabs of 31 of 32 (97%) subjects with analyzable specimens. The most common type was HPV16 (44%).

27 (82%) subjects completed treatment per protocol—CR: 4 (15%); PR: 12 (44%); SD: 9 (33%); PD: 2 (7%) (1 with a superficially invasive cancer and 1 with new PAIN 2-3). Six subjects did not complete treatment because of discomfort (1), poor compliance (4), and CR after 4 cycles (1).

26 of 33 subjects (79%) reported adverse events likely related to treatment. Most were mild or moderate, including self-limited, localized, superficial ulcerations in the disease area (2 mild, 19 moderate, 1 severe), discomfort (4 mild, 14 moderate), itching (1 mild, 3 moderate), and bleeding (6 mild). Seven (21%) had mild transient proteinuria.

Conclusions

Topical cidofovir is a well-tolerated and effective treatment for PAIN 2-3 in HIV-positive patients. A larger study is warranted.

Declarations

Acknowledgements

This article has been published as part of Infectious Agents and Cancer Volume 5 Supplement 1, 2010: Proceedings of the 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI).The full contents of the supplement are available online at http://www.biomedcentral.com/1750-9378/5?issue=S1.

Authors’ Affiliations

(1)
Department of Obstetrics and Gynecology, Boston University Medical Center
(2)
Department of Surgery, Mount Sinai School of Medicine
(3)
Montefiore Medical Center and Einstein Cancer Center
(4)
Department of Medicine, University of California
(5)
Division of Infectious Diseases, Weill Cornell Medical College
(6)
Department of Biostatistics, University of Arkansas for Medical Sciences
(7)
Division of Infectious Diseases, Beth Israel Deaconess Medical Center
(8)
Division of Hematology and Oncology, Virginia Mason Medical Center and Department of Hematology, University of Washington

Copyright

© Stier et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.

Advertisement